NIH-Funded ACTIV/ACTIV-Associated Clinical Trials

Company Therapeutic Class Administration New/
Repurposed		 Estimated
End Date

ACTIV-1 Inpatient
AbbVie Cenicriviroc Immune Modulator Oral New Q4 2021
BMS Orencia® (abatacept) Immune Modulator Intravenous Repurposed Q4 2021
Janssen Remicade® (Infliximab) Immune Modulator Intravenous Repurposed Q4 2021

ACTIV-2 Outpatient
AstraZeneca AZD7442 Monoclonal Antibody Cocktail Intramuscular New Ended
AstraZeneca AZD7442 Monoclonal Antibody Cocktail Intravenous New Ended
Brii Biosciences Brii-196 & Brii-198 Monoclonal Antibody Cocktail Intravenous New Q4 2021
Bristol Myers Squibb BMS-986414 and BMS-986413 (also known as C135-LS and C144-LS) Monoclonal Antibody Cocktail Subcutaneous Injection New Q4 2021
Eli Lilly LY-CoV-555 Monoclonal Antibody Single Intravenous New Q1 2021
SAB Biotherapeutics SAB-185 Polyclonal antibody Intravenous New Q1 2022
Sagent Camostat Mesylate Antiviral Oral Repurposed Ended
Synairgen SNG001 IFN-beta Immune Modulator Inhaled Repurposed Q4 2021

ACTIV-3 Inpatient
AstraZeneca AZD7442 Monoclonal Antibody Cocktail Intravenous New Q3 2021
Brii Biosciences Brii-196 & Brii-198 Monoclonal Antibody Cocktail Intravenous New Ended
Eli Lilly LY-CoV-555 Monoclonal Antibody Single Intravenous New Ended
Giliad/NeuroRx ZyesamiTM (aviptadil acetate) and Veklury® (remdesivir)  Immune Modulator/Antiviral Intravenous Repurposed Q4 2021
GSK-Vir VIR-7831 Monoclonal Antibody Single Intravenous New Ended
Molecular Partners/Novartis Ensovibep (MP0420) DARPin Intravenous New Q1 2022

ACTIV-4

Outpatients
BMS/Pfizer Eliquis ® (apixaban) Anticoagulant Oral Repurposed Ended
BMS/Pfizer Aspirin Antiplatelet Oral Repurposed Ended

Inpatients
Other Un-fractionated (UF) Heparin Anticoagulant Intravenous Repurposed Ended
Other Unfractionated Heparin and P2Y12 Inhibitors Anticoagulant Intravenous Repurposed Q3 2021
Other Low Molecular Weight (LMW) Heparin Anticoagulant Injection Repurposed Ended

Convalescent
BMS/Pfizer Eliquis ® (apixaban) Anticoagulant Oral Repurposed Q4 2021

Host Tissue
Constant Therapeutics TXA127 Mas Receptor Agonist IV New Q4 2022
Trevena TRV027 AT1R Beta-arrestin Agonist IV New Q4 2022

ACTIV-5 Inpatient
AbbVie/Boehringer Ingelheim SkyrisiTM (risankizumab) Immune Modulator Intravenous Repurposed Ended
Humanigen Lenzilumab Immune Modulator Intravenous New Q4 2021
Alexion Danicopan

Factor D Inhibitor

 Oral New Q4 2021

ACTIV-6 Outpatient
Ingenus Ivermectin Immune Modulator/Antiviral Oral Repurposed Q1 2022
Apotex Fluvoxamine Immune Modulator/Antiviral Oral Repurposed Q1 2022
GlaxoSmithKline Fluticasone Immune Modulator Oral Repurposed Q1 2022

ACTIV-Associated

Adaptive COVID-19 Treatment Trial (ACTT) Inpatient
Gilead Veklury® (remdesivir) Antiviral Intravenous Repurposed Ended
Gilead/Eli Lilly Veklury® (remdesivir) and Olumiant® (baricitinib) Antiviral/Anti-Inflammatory Intravenous/Oral Repurposed Ended
Gilead/Merck KGaA Veklury® (remdesivir) and Rebif® (IFN-beta ) Antiviral/Immune Modulator Injection Repurposed Ended
Gilead/Eli Lilly/Other Veklury® (remdesivir) and Olumiant® (baricitinib) or Dexamethasone Antiviral/Anti-Inflammatory/
Immune Modulator		 Intravenous/Oral Repurposed Ended

Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC)
Gilead/Other Veklury® (remdesivir) and Hyperimmune
Intravenous Immunoglobulin (hIVIG)		 Antiviral Intravenous N/A Q3 2021

Convalescent Plasma in Outpatients with COVID-19 (C3PO)

Other Convalescent Plasma Convalescent Plasma Intravenous N/A Ended

Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients (CONTAIN COVID-19)
Other Convalescent Plasma Convalescent Plasma Intravenous N/A Q2 2021

Passive Immunity Trial of Our Nation (PassItOn) Inpatient
Other Convalescent Plasma Convalescent Plasma Intravenous N/A Q2 2021

This page last reviewed on August 13, 2021